Is Procept Biorobotics Stock a Good Investment?
Procept Biorobotics Investment Advice | PRCT |
- Examine Procept Biorobotics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Procept Biorobotics' leadership team and their track record. Good management can help Procept Biorobotics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Procept Biorobotics' business and its evolving consumer preferences.
- Compare Procept Biorobotics' performance and market position to its competitors. Analyze how Procept Biorobotics is positioned in terms of product offerings, innovation, and market share.
- Check if Procept Biorobotics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Procept Biorobotics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Procept Biorobotics Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Procept Biorobotics Corp is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Procept Biorobotics Stock
Researching Procept Biorobotics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 93.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.75. Procept Biorobotics Corp had not issued any dividends in recent years.
To determine if Procept Biorobotics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Procept Biorobotics' research are outlined below:
| Procept Biorobotics generated a negative expected return over the last 90 days | |
| Procept Biorobotics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 224.5 M. Net Loss for the year was (91.41 M) with profit before overhead, payroll, taxes, and interest of 137.1 M. | |
| Procept Biorobotics Corp currently holds about 269.81 M in cash with (99.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.05. | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: PROCEPT BioRobotics Corp Announces Promising Results from WATER III Trial |
Procept Biorobotics Quarterly Liabilities And Stockholders Equity |
|
Procept Biorobotics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Procept Biorobotics Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Procept Biorobotics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Procept Biorobotics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Procept Biorobotics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-04 | 2022-06-30 | -0.48 | -0.43 | 0.05 | 10 | ||
2022-05-05 | 2022-03-31 | -0.47 | -0.39 | 0.08 | 17 | ||
2024-10-30 | 2024-09-30 | -0.49 | -0.4 | 0.09 | 18 | ||
2024-02-27 | 2023-12-31 | -0.44 | -0.54 | -0.1 | 22 | ||
2021-11-04 | 2021-09-30 | -0.42 | -1.22 | -0.8 | 190 |
Procept Biorobotics Target Price Consensus
Procept target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Procept Biorobotics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Procept analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Procept stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Procept Biorobotics Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationProcept Biorobotics Target Price Projection
Procept Biorobotics' current and average target prices are 62.33 and 102.75, respectively. The current price of Procept Biorobotics is the price at which Procept Biorobotics Corp is currently trading. On the other hand, Procept Biorobotics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Procept Biorobotics Market Quote on 26th of March 2025
Target Price
Analyst Consensus On Procept Biorobotics Target Price
Procept Biorobotics Analyst Ratings
Procept Biorobotics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Procept Biorobotics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Procept Biorobotics' financials, market performance, and future outlook by experienced professionals. Procept Biorobotics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Procept Biorobotics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Procept Biorobotics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Procept Biorobotics Corp backward and forwards among themselves. Procept Biorobotics' institutional investor refers to the entity that pools money to purchase Procept Biorobotics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 757.4 K | T. Rowe Price Associates, Inc. | 2024-12-31 | 713.9 K | Federated Hermes Inc | 2024-12-31 | 658.1 K | Mirae Asset Global Etfs Holdings Ltd. | 2024-12-31 | 631.1 K | Lord, Abbett & Co Llc | 2024-12-31 | 625.2 K | Bank Of America Corp | 2024-12-31 | 623.4 K | Jpmorgan Chase & Co | 2024-12-31 | 615.2 K | D. E. Shaw & Co Lp | 2024-12-31 | 607.4 K | Axa Sa | 2024-12-31 | 582.4 K | Fmr Inc | 2024-12-31 | 8.2 M | Vanguard Group Inc | 2024-12-31 | 5.1 M |
Procept Biorobotics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.43 B.Market Cap |
|
Procept Biorobotics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.20) | (0.21) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.23) | (0.24) |
Determining Procept Biorobotics' profitability involves analyzing its financial statements and using various financial metrics to determine if Procept Biorobotics is a good buy. For example, gross profit margin measures Procept Biorobotics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Procept Biorobotics' profitability and make more informed investment decisions.
Procept Biorobotics' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Procept Biorobotics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Procept Biorobotics Corp. Check Procept Biorobotics' Beneish M Score to see the likelihood of Procept Biorobotics' management manipulating its earnings.
Evaluate Procept Biorobotics' management efficiency
Procept Biorobotics Corp has return on total asset (ROA) of (0.1287) % which means that it has lost $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2677) %, meaning that it created substantial loss on money invested by shareholders. Procept Biorobotics' management efficiency ratios could be used to measure how well Procept Biorobotics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2025. Return On Capital Employed is likely to drop to -0.21 in 2025. At this time, Procept Biorobotics' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 381.7 K in 2025, whereas Total Current Liabilities is likely to drop slightly above 31.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.72 | 8.10 | |
| Tangible Book Value Per Share | 7.70 | 8.08 | |
| Enterprise Value Over EBITDA | (48.10) | (50.50) | |
| Price Book Value Ratio | 10.43 | 10.96 | |
| Enterprise Value Multiple | (48.10) | (50.50) | |
| Price Fair Value | 10.43 | 10.96 | |
| Enterprise Value | 1.6 B | 1.4 B |
Procept Biorobotics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.052 |
Basic technical analysis of Procept Stock
As of the 26th of March, Procept Biorobotics holds the Risk Adjusted Performance of (0.11), coefficient of variation of (715.77), and Variance of 11.33. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Procept Biorobotics, as well as the relationship between them.Procept Biorobotics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Procept Biorobotics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Procept Biorobotics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Procept Biorobotics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Procept Biorobotics' Outstanding Corporate Bonds
Procept Biorobotics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Procept Biorobotics Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Procept bonds can be classified according to their maturity, which is the date when Procept Biorobotics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PROCTER GAMBLE 645 Corp BondUS742718BH18 | View | |
| PROCTER GAMBLE 55 Corp BondUS742718CB39 | View | |
| PROCTER GAMBLE 555 Corp BondUS742718DF34 | View | |
| PROCTER GAMBLE 58 Corp BondUS742718DB20 | View | |
| PROCTER GAMBLE 245 Corp BondUS742718ER62 | View | |
| PROCTER GAMBLE 27 Corp BondUS742718EP07 | View | |
| PROCTER GAMBLE 285 Corp BondUS742718EV74 | View | |
| PG 23 01 FEB 32 Corp BondUS742718FW49 | View |
Understand Procept Biorobotics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Procept Biorobotics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (2.32) | |||
| Mean Deviation | 2.65 | |||
| Coefficient Of Variation | (715.77) | |||
| Standard Deviation | 3.37 | |||
| Variance | 11.33 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (2.33) | |||
| Maximum Drawdown | 14.42 | |||
| Value At Risk | (5.38) | |||
| Potential Upside | 5.07 | |||
| Skewness | 0.2943 | |||
| Kurtosis | 0.1486 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (2.32) | |||
| Mean Deviation | 2.65 | |||
| Coefficient Of Variation | (715.77) | |||
| Standard Deviation | 3.37 | |||
| Variance | 11.33 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.48) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (2.33) | |||
| Maximum Drawdown | 14.42 | |||
| Value At Risk | (5.38) | |||
| Potential Upside | 5.07 | |||
| Skewness | 0.2943 | |||
| Kurtosis | 0.1486 |
Consider Procept Biorobotics' intraday indicators
Procept Biorobotics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Procept Biorobotics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Procept Biorobotics Corporate Filings
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 28th of February 2025 Other Reports | ViewVerify | |
10K | 27th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Procept Stock media impact
Far too much social signal, news, headlines, and media speculation about Procept Biorobotics that are available to investors today. That information is available publicly through Procept media outlets and privately through word of mouth or via Procept internal channels. However, regardless of the origin, that massive amount of Procept data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Procept Biorobotics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Procept Biorobotics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Procept Biorobotics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Procept Biorobotics alpha.
Procept Biorobotics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Procept Biorobotics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Procept Biorobotics Corp Historical Investor Sentiment
Investor biases related to Procept Biorobotics' public news can be used to forecast risks associated with an investment in Procept. The trend in average sentiment can be used to explain how an investor holding Procept can time the market purely based on public headlines and social activities around Procept Biorobotics Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Procept Biorobotics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Procept Biorobotics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Procept Biorobotics news discussions. The higher the estimate score, the more favorable the investor's outlook on Procept Biorobotics.
Procept Biorobotics Maximum Pain Price Across May 16th 2025 Option Contracts
Procept Biorobotics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Procept Biorobotics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Procept Biorobotics' options.
Procept Biorobotics Corporate Management
| Matthew CFA | Vice Relations | Profile | |
| Hisham Shiblaq | Executive Officer | Profile | |
| Stacey Porter | Chief Officer | Profile | |
| Minni Vittal | VP Officer | Profile | |
| Alaleh Nouri | Chief EVP | Profile |
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.